Neurocrine to present new real-world evidence of Ingrezza use in patients

Neurocrine (NBIX) Biosciences announced the presentation of new real-world evidence demonstrating that adult patients with tardive dyskinesia receiving INGREZZA, or valbenazine, capsules showed higher treatment persistence compared to those on AUSTEDO XR, or deutetrabenazine. The findings are being presented at the Academy of Managed Care Pharmacy 2026 Annual Meeting in Nashville. This retrospective, real-world claims analysis is the first published study to directly compare treatment persistence between INGREZZA and AUSTEDO XR in matched tardive dyskinesia, TD, patient cohorts. Over a six-month follow-up period, patients treated with INGREZZA demonstrated statistically greater treatment continuation and lower switching rates than those receiving AUSTEDO XR. Differences in treatment persistence emerged early and were sustained throughout the six-month period, highlighting durable treatment continuation patterns. The analysis used IQVIA’s U.S. Longitudinal Access and Adjudication Data, integrating pharmacy and medical claim information. The study period ranged from September 1, 2022 to March 31, 2025, including adult patients with TD who initiated either INGREZZA or AUSTEDO XR between March 1, 2023 and September 30, 2024. Over the 6-month follow-up period: Significantly more patients persisted with their initial TD therapy in the cohort who started on INGREZZA compared to those who started on AUSTEDO XR; Switching to another TD therapy at any time during the follow-up period was significantly less frequent in the INGREZZA cohort compared to AUSTEDO XR; the median time to discontinuation or switch from the initial therapy was 129 days for the AUSTEDO XR cohort, while the median was not reached for the INGREZZA cohort, indicating significantly longer time to discontinuation or switch. Measure